The orphan status is huge it means no competition for 10 years $$$$$$$$$$$$$$$$$$$$$$
3/209 This week, Advanced cell also announced it had secured $5 million in funding to file an IND application. Earlier this month, Advanced Cell reported it had also brought in $400,000, in part from Korean biotech CHA Biotech Co. Ltd. The Korean company was making a final payment for its recently formed international joint venture with Advanced Cell, which is called Stem Cell & Regenerative Medicine International.
The two companies formed the Worcester-based joint venture in December. Stem Cell & Regenerative Medicine intends to use Advanced Cell’s hemangioblast cell technology to develop human blood cells.
What this amounts to is the FDA did not like the way phase 1 was conducted to see engraftment and read more letters was not good enough. We can now see what happened in DEC.and why all the delays.
Drop the FDA save the money for the trials in the E.U. I also believe the FDA will never approve ANY stem cell treatment no matter how well it works.
When they can prove engraftment why was that not good enough? They have the ability to look inside the eye and see progress. I do not get it why put patients through all the bs just to trick them
The up list.................The Registrant’s common stock is currently quoted on the OTCQB, under the symbol “OCAT.” Upon commencement of trading on the NASDAQ Global Market on February 26, 2015, the Registrant’s common stock will be quoted under the symbol “OCAT.”
Dr. Eddy Anglade, Chief Medical Officer of Ocata Therapeutics, said: “We are pleased to receive ATMP status from the EMA. We view this as an important step to further enable the development of our novel biological therapy in the EU with the aim of seeking marketing authorization approval. Additionally, we interpret this as a favorable indication for how the European regulators view our therapy.”